

# FerrÃ¡n CatalÃ¡-LÃ¡pez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4231539/publications.pdf>

Version: 2024-02-01

179  
papers

127,690  
citations

8172

76  
h-index

3260

185  
g-index

217  
all docs

217  
docs citations

217  
times ranked

147028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
2	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	6.3	7,664
3	Global, regional, and national ageâ€“sex specific all-cause and cause-specific mortality for 240 causes of death, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	6.3	5,847
4	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
5	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
6	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
7	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
8	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
9	The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Annals of Internal Medicine, 2015, 162, 777-784.	2.0	4,590
10	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	1.2	4,468
11	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology, 2017, 3, 524.	3.4	4,254
12	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
13	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
14	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
15	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
16	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	1.2	2,705
17	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	4.9	2,625
18	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	3.4	2,269

#	ARTICLE	IF	CITATIONS
19	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	6.3	2,184
20	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
21	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005
22	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 439-458.	4.9	2,005
23	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
24	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
25	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
26	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
27	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
28	Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology, The</i> , 2017, 16, 877-897.	4.9	1,521
29	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 88-106.	4.9	1,512
30	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 165.	3.8	1,492
31	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	3.4	1,260
32	Global, regional, and national levels and causes of maternal mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 980-1004.	6.3	1,230
33	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. <i>Lancet Public Health, The</i> , 2022, 7, e105-e125.	4.7	1,199
34	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 56-87.	4.9	1,064
35	Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. <i>Neuroepidemiology</i> , 2015, 45, 161-176.	1.1	1,002
36	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. <i>New England Journal of Medicine</i> , 2018, 379, 2429-2437.	13.9	959

#	ARTICLE	IF	CITATIONS
37	The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. <i>Injury Prevention</i> , 2016, 22, 3-18.	1.2	898
38	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
39	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	6.3	786
40	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
41	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. <i>JAMA Oncology</i> , 2022, 8, 420.	3.4	719
42	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
43	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
44	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 957-979.	6.3	609
45	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
46	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
47	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. <i>BMJ: British Medical Journal</i> , 2019, 364, I94.	2.4	558
48	Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. <i>PLoS Medicine</i> , 2016, 13, e1002028.	3.9	497
49	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
50	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. <i>JAMA Pediatrics</i> , 2016, 170, 267.	3.3	479
51	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , 2016, 3, e361-e387.	2.1	461
52	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
53	Global, regional, and national burden of brain and other CNS cancer, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 376-393.	4.9	359
54	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335

#	ARTICLE	IF	CITATIONS
55	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	6.3	330
56	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	3.3	306
57	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
58	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
59	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. <i>Lancet, The</i> , 2019, 393, 2233-2260.	6.3	283
60	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , 2018, 3, 375.	3.0	271
61	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. <i>PLoS ONE</i> , 2017, 12, e0180355.	1.1	218
62	Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet, The</i> , 2017, 389, 1981-2004.	6.3	204
63	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology, The</i> , 2019, 20, 1211-1225.	5.1	199
64	Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study. <i>Neuroepidemiology</i> , 2015, 45, 230-236.	1.1	186
65	How to properly use the PRISMA Statement. <i>Systematic Reviews</i> , 2021, 10, 117.	2.5	180
66	Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. <i>Lancet, The</i> , 2018, 391, 1783-1798.	6.3	172
67	Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 89-105.	4.0	164
68	Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet, The</i> , 2017, 389, 2005-2030.	6.3	163
69	Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. <i>Neuroepidemiology</i> , 2015, 45, 203-214.	1.1	159
70	Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. <i>Rheumatology International</i> , 2014, 34, 1489-1496.	1.5	142
71	Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015. <i>Lancet, The</i> , 2018, 391, 1799-1829.	6.3	127
72	Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. <i>BMC Psychiatry</i> , 2012, 12, 168.	1.1	115

#	ARTICLE	IF	CITATIONS
73	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i96-i114.	1.2	103
74	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. <i>PLoS ONE</i> , 2017, 12, e0169575.	1.1	102
75	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2021, 398, 1593-1618.	6.3	92
76	The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Oncology</i> , The, 2022, 23, 27-52.	5.1	90
77	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet</i> , The, 2020, 396, 693-724.	6.3	87
78	The Quality of Reporting Methods and Results in Network Meta-Analyses: An Overview of Reviews and Suggestions for Improvement. <i>PLoS ONE</i> , 2014, 9, e92508.	1.1	82
79	Reproducible research practices are underused in systematic reviews of biomedical interventions. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 8-18.	2.4	79
80	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. <i>Lancet</i> , The, 2021, 398, 1317-1343.	6.3	79
81	Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. <i>PLoS Medicine</i> , 2016, 13, e1001971.	3.9	75
82	The increasing burden of mental and neurological disorders. <i>European Neuropsychopharmacology</i> , 2013, 23, 1337-1339.	0.3	69
83	Reporting guidelines of health research studies are frequently used inappropriately. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 87-94.	2.4	52
84	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. <i>Medicina Clínica</i> , 2015, 145, 511-519.	0.3	49
85	Flaws in the application and interpretation of statistical analyses in systematic reviews of therapeutic interventions were common: a cross-sectional analysis. <i>Journal of Clinical Epidemiology</i> , 2018, 95, 7-18.	2.4	48
86	Adherence to Evidence-Based Therapies After Acute Coronary Syndrome: A Retrospective Population-Based Cohort Study Linking Hospital, Outpatient, and Pharmacy Health Information Systems in Valencia, Spain. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 247-257.	2.2	46
87	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. <i>Injury Prevention</i> , 2020, 26, i125-i153.	1.2	44
88	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	1.2	44
89	Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder. <i>JAMA Pediatrics</i> , 2022, 176, e216401.	3.3	44
90	Control of arterial hypertension in Spain. <i>Journal of Hypertension</i> , 2012, 30, 168-176.	0.3	43

#	ARTICLE	IF	CITATIONS
91	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. <i>Medicina Clínica</i> , 2012, 139, 421-429.	0.3	41
92	Measuring the burden of disease and injury in Spain using disability-adjusted life years: An updated and policy-oriented overview. <i>Public Health</i> , 2012, 126, 1024-1031.	1.4	37
93	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2015, 4, 19.	2.5	37
94	The burden of premature mortality in Spain using standard expected years of life lost: a population-based study. <i>BMC Public Health</i> , 2011, 11, 787.	1.2	36
95	The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 262-266.	0.1	33
96	The Global Research Collaboration of Network Meta-Analysis: A Social Network Analysis. <i>PLoS ONE</i> , 2016, 11, e0163239.	1.1	33
97	Global collaborative networks on meta-analyses of randomized trials published in high impact factor medical journals: a social network analysis. <i>BMC Medicine</i> , 2014, 12, 15.	2.3	30
98	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , 2019, 10, 17.	2.6	30
99	Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controlled clinical trials. <i>Veterinary Microbiology</i> , 2015, 180, 1-9.	0.8	28
100	The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. <i>Systematic Reviews</i> , 2016, 5, 6.	2.5	28
101	Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?. <i>BMC Health Services Research</i> , 2011, 11, 75.	0.9	27
102	Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open</i> , 2020, 10, e034463.	0.8	27
103	Coauthorship and Institutional Collaborations on Cost-Effectiveness Analyses: A Systematic Network Analysis. <i>PLoS ONE</i> , 2012, 7, e38012.	1.1	25
104	Carga de enfermedad en adolescentes y jóvenes en España. <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 80-85.	1.0	25
105	When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins. <i>PLoS ONE</i> , 2013, 8, e69462.	1.1	25
106	Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. <i>Systematic Reviews</i> , 2017, 6, 69.	2.5	24
107	Mapping of global scientific research in comorbidity and multimorbidity: A cross-sectional analysis. <i>PLoS ONE</i> , 2018, 13, e0189091.	1.1	24
108	Does the development of new medicinal products in the European Union address global and regional health concerns?. <i>Population Health Metrics</i> , 2010, 8, 34.	1.3	23

#	ARTICLE	IF	CITATIONS
109	Alzheimer's Disease and Cancer: Current Epidemiological Evidence for a Mutual Protection. <i>Neuroepidemiology</i> , 2014, 42, 121-122.	1.1	23
110	Citation impact was highly variable for reporting guidelines of health research: a citation analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 96-104.	2.4	22
111	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	0.7	19
112	Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. <i>European Journal of Public Health</i> , 2008, 18, 674-680.	0.1	16
113	Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 99-108.	0.8	13
114	Declaración de transparencia: un paso hacia la presentación completa de artículos de investigación. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 63-64.	1.0	13
115	Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study. <i>Medicina Clínica</i> , 2013, 140, 343-350.	0.3	12
116	Disability-adjusted Life Years Lost to Ischemic Heart Disease in Spain. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 968-975.	0.4	12
117	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 1-3.	1.0	12
118	Coste-efectividad del tratamiento farmacológico del trastorno por déficit de atención e hiperactividad en niños y adolescentes: síntesis cualitativa de la evidencia científica. <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 168-177.	1.0	11
119	La propiedad transitiva en los ensayos clínicos controlados: si B es mejor que A y C es mejor que B, ¿C es mejor que A?. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 597-602.	0.6	11
120	The national burden of cerebrovascular diseases in Spain: A population-based study using disability-adjusted life years. <i>Medicina Clínica</i> , 2015, 144, 353-359.	0.3	11
121	Risk of mortality among children, adolescents, and adults with autism spectrum disorder or attention deficit hyperactivity disorder and their first-degree relatives: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2017, 6, 189.	2.5	11
122	Trends of uncontrolled blood pressure in Spain. <i>Journal of Hypertension</i> , 2013, 31, 630-631.	0.3	10
123	Association of Anorexia Nervosa With Risk of Cancer. <i>JAMA Network Open</i> , 2019, 2, e195313.	2.8	10
124	Prevalence and comorbidity of autism spectrum disorder in Spain: study protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2019, 8, 141.	2.5	10
125	Reporting guidelines for health research: protocol for a cross-sectional analysis of the EQUATOR Network Library. <i>BMJ Open</i> , 2019, 9, e022769.	0.8	10
126	Clinical Management of Abnormal Cytology Test Results and Costs Associated With the Prevention of Cervical Cancer in Spain. <i>Journal of Lower Genital Tract Disease</i> , 2010, 14, 311-318.	0.9	8



#	ARTICLE	IF	CITATIONS
127	Uso de medicamentos antihipertensivos en España: tendencias nacionales en el periodo 2000-2012. Revista Espanola De Cardiologia, 2015, 68, 899-903.	0.6	8
128	Prevalence and comorbidity of attention deficit hyperactivity disorder in Spain: study protocol for extending a systematic review with updated meta-analysis of observational studies. Systematic Reviews, 2019, 8, 49.	2.5	8
129	Use of Antihypertensive Drugs in Spain: National Trends From 2000 to 2012. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 899-903.	0.4	7
130	Evaluación del efecto de los tratamientos utilizando comparaciones indirectas. Revista Espanola De Cardiologia, 2013, 66, 156-157.	0.6	6
131	The Transitive Property Across Randomized Controlled Trials: If B Is Better Than A, and C Is Better Than B, Will C Be Better Than A?. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 597-602.	0.4	6
132	Benefits and Risks of Intraoperative High Inspired Oxygen Therapy: Firm Conclusions Are Still Far Off. Anesthesiology, 2014, 120, 1051-1052.	1.3	6
133	Anorexia nervosa and cancer: a protocol for a systematic review and meta-analysis of observational studies. Systematic Reviews, 2017, 6, 137.	2.5	6
134	Impacto de la asignación de la insuficiencia cardiaca como causa básica de defunción en el cálculo de la mortalidad prematura cardiovascular en España. Revista Espanola De Cardiologia, 2013, 66, 1004-1005.	0.6	5
135	Hyperosmolar therapy for acute brain injury: study protocol for an umbrella review of meta-analyses and an evidence mapping. BMJ Open, 2020, 10, e033913.	0.8	5
136	New drug development. Lancet, The, 2011, 377, 902.	6.3	4
137	Cost-effectiveness of iodinated contrast media for CT scanning in Spain: a decision-based analysis. Imaging in Medicine, 2012, 4, 193-199.	0.0	4
138	Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis. Diabetologia, 2012, 55, 2547-2548.	2.9	4
139	Evaluación económica de intervenciones en enfermedades oncológicas en España: revisión sistemática y análisis comparativo. Farmacia Hospitalaria, 2012, 36, 141-147.	0.6	4
140	Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: many concerns for new tools of evidence synthesis?. Osteoporosis International, 2013, 24, 1927-1928.	1.3	4
141	Evaluation of Comparative Treatment Effects Using Indirect Comparisons. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 156-157.	0.4	4
142	Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Qualitative synthesis of scientific evidence. Revista De Psiquiatria Y Salud Mental (English Edition), 2013, 6, 168-177.	0.2	4
143	La carga de enfermedad atribuible a los principales factores de riesgo en los países de Europa occidental: el reto de controlar los factores de riesgo cardiovascular. Revista Espanola De Cardiologia, 2013, 66, 591-593.	0.6	4
144	Alzheimer's disease and cancer: the need of putting research into context with previous published systematic reviews. Journal of Cancer Research and Clinical Oncology, 2015, 141, 569-570.	1.2	4

#	ARTICLE	IF	CITATIONS
145	Revisiones rápidas para la síntesis de la evidencia. Medicina Clínica, 2017, 148, 424-428.	0.3	3
146	Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-aldosterone System. Revista Española De Cardiología (English Ed ), 2013, 66, 412-415.	0.4	2
147	Burden of disease in adolescents and young people in Spain. Revista De Psiquiatría Y Salud Mental (English Edition), 2013, 6, 80-85.	0.2	2
148	Clinical equipoise and systematic reviews of randomized controlled trials. Medicina Clínica (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	2
149	Rapid reviews for evidence synthesis. Medicina Clínica (English Edition), 2017, 148, 424-428.	0.1	2
150	Estrategias de transferencia del conocimiento para mejorar la atención sanitaria. Medicina Clínica, 2018, 151, 239-241.	0.3	2
151	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. BMC Medical Informatics and Decision Making, 2021, 21, 241.	1.5	2
152	Declaración de transparencia: promoviendo una publicación más completa, honesta y adecuada de los artículos científicos. Revista Española De Salud Pública, 2014, 88, 181-186.	0.3	2
153	Uso de olmesartán en la prevención o retraso de la nefropatía diabética: algunas consideraciones. Revista Española De Cardiología, 2012, 65, 678-679.	0.6	1
154	Safety of aprotinin in adult cardiac surgery: Revisiting the validity of a mixed-treatment comparison meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 610.	0.4	1
155	Disease Burden Attributable to Major Risk Factors in Western European Countries: The Challenge of Controlling Cardiovascular Risk Factors. Revista Española De Cardiología (English Ed ), 2013, 66, 591-593.	0.4	1
156	Endothelin receptor antagonists-induced hepatotoxicity. Internal Medicine Journal, 2013, 43, 609-610.	0.5	1
157	Statins Use and Risk of Cataracts. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 344-345.	1.0	1
158	Design and methodological characteristics of studies using observational routinely collected health data for investigating the link between cancer and neurodegenerative diseases: protocol for a meta-research study. BMJ Open, 2022, 12, e058738.	0.8	1
159	Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations. Revista Española De Cardiología (English Ed ), 2012, 65, 678-679.	0.4	0
160	Evaluating New Health Technologies and Disease Burden in Developed Countries. Value in Health, 2012, 15, 987-988.	0.1	0
161	Revisión de las evaluaciones económicas de intervenciones en enfermedades cardiovasculares en España. Farmacia Hospitalaria, 2012, 36, 163-165.	0.6	0
162	Global health priorities and research funding. Lancet Infectious Diseases, The, 2013, 13, 652.	4.6	0

#	ARTICLE	IF	CITATIONS
163	Impact of Assigning Heart Failure as the Underlying Cause of Death on the Calculation of Premature Mortality Due to Cardiovascular Disease in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 1004-1005.	0.4	0
164	Clinical evidence from randomized trials, network meta-analyses, and conflicts of interests. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 731-732.	0.4	0
165	Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons. <i>European Journal of Cancer</i> , 2013, 49, 984-985.	1.3	0
166	Progressive chronic kidney disease and dual inhibition of the renin-angiotensin-aldosterone system. <i>Preventive Medicine</i> , 2014, 60, 136.	1.6	0
167	Antihypertensive Medication: On the Right Path? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> 10.784314 rgBT / 0v	0.4	0
168	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 511-519.	0.1	0
169	The national burden of cerebrovascular diseases in Spain: A population-based study using disability-adjusted life years. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 353-359.	0.1	0
170	Prescripción de fármacos antihipertensivos: ¿en el buen camino? Respuesta. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 1191-1192.	0.6	0
171	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2016, 9, 1-3.	0.2	0
172	Quality of Methods and Results Reporting in Cost-effectiveness Analyses of Cardiovascular Interventions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 876-877.	0.4	0
173	Declaration of transparency: A step towards complete reporting of research articles. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2016, 9, 63-64.	0.2	0
174	Improving transparency of methods and results in cost-effectiveness analyses for cancer prevention, treatment and control. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 43-45.	0.1	0
175	Mejoria de la transparencia de métodos y resultados en los análisis coste-efectividad de intervenciones para prevenir, tratar y controlar el cáncer. <i>Medicina Clínica</i> , 2017, 148, 43-45.	0.3	0
176	The treatment of attention deficit hyperactivity disorder in children and adolescents: Epidemiology, multimorbidity and integrated health services. <i>Anales De Pediatría (English Edition)</i> , 2018, 88, 181-182.	0.1	0
177	Knowledge translation strategies to improve health care. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 239-241.	0.1	0
178	Digital health interventions for children with ADHD. <i>The Lancet Digital Health</i> , 2020, 2, e150-e151.	5.9	0
179	Cost-effectiveness analyses in neuropsychiatry and mental health. <i>Actas Espanolas De Psiquiatria</i> , 2017, 45, 127-36.	0.1	0